Protek: peers
Protek beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Protek, MD Medical Group Investments, InMode Ltd., Adlai Nortye, Korian: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Protekbase PRTK.ME · 🇷🇺 RU Percentile in Healthcare Percentile in Russia | Pharmacy Chain 36.6 APTK.ME · 🇷🇺 RU Percentile in Healthcare Percentile in Russia | MD Medical Group Investments MD6B.F · 🇷🇺 RU Percentile in Healthcare Percentile in Russia | Corvus Pharmaceuticals, Inc. CRVS · 🇺🇸 US Percentile in Healthcare Percentile in USA | InMode Ltd. INMD · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Adlai Nortye ANL · 🇰🇾 KY Percentile in Healthcare Percentile in Cayman Islands | Korian KORI.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | MoonLake Immunotherapeutics MLTX · 🇨🇭 CH Percentile in Healthcare Percentile in Switzerland | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $846 Mlast known, Jan 1, 2020 · Market dataLast known value: no current one4th of 8 | $661 MNov 19, 2026 · Market data7th of 8 | $216 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one8th of 8 | $863 MOct 21, 2026 · Market data1st of 8 | $859 MAug 1, 2026 · Market data2nd of 8 | $853 MAug 1, 2026 · Market data3rd of 8 | $830 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $830 MOct 20, 2026 · Market data6th of 8 | $838 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $4.4 BFY2017 · Wikidata2nd of 3 | —— | —— | —— | $371 MFY2025 · SEC3rd of 3 | —— | $6.0 BFY2025 · ESEF1st of 3 | —— | $4.4 B3 ranked |
| Net income (Higher is better) | $101 MFY2017 · Wikidata1st of 6 | —— | —— | $-15 MFY2025 · SEC4th of 6 | $94 MFY2025 · SEC2nd of 6 | $-52 MFY2024 · SEC5th of 6 | $2 MFY2025 · ESEF3rd of 6 | $-227 MFY2025 · SEC6th of 6 | $-7 M6 ranked |
| Employees (Better neither way: ranked highest first) | 12,0002012 · Profile2nd of 4 | —— | —— | 37December 31, 2025 · Profile4th of 4 | 660December 31, 2025 · Profile3rd of 4 | —— | 57,5182022 · Profile1st of 4 | —— | 6,3304 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | -6.2%FY2025 · SEC2nd of 216th20th | ———— | +4.7%FY2025 · ESEF1st of 236th56th | ———— | -0.7%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | -6.6%FY2025 · SEConly one with it15th20th | ———— | ———— | ———— | -6.6%— |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | -36.4%FY2025 · SEConly one with it13th34th | ———— | ———— | ———— | -36.4%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | 78.5%FY2025 · SEConly one with it79th86th | ———— | ———— | ———— | 78.5%— |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | 23.1%FY2025 · SEC1st of 291st92nd | ———— | 5.7%FY2025 · ESEF2nd of 266th52nd | ———— | 14.4%2 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | 25.3%FY2025 · SEC1st of 292nd93rd | ———— | 0.0%FY2025 · ESEF2nd of 260th30th | ———— | 12.7%2 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | 22.8%FY2025 · SEConly one with it91st83rd | ———— | ———— | ———— | 22.8%— |
| Return on equity (Higher is better) | ———— | ———— | ———— | -32.6%FY2025 · SEC3rd of 552nd23rd | 13.5%FY2025 · SEC1st of 586th79th | -103.2%FY2024 · SEC5th of 524th— | 0.0%FY2025 · ESEF2nd of 573rd25th | -60.5%FY2025 · SEC4th of 538th12th | -32.6%5 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 9.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 2.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 14.1×price Oct 21, 2026 · Market data1st of 289th93rd | 1.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 33.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 2.7×price Oct 20, 2026 · Market data2nd of 246th— | 8.4×2 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | -3.8%price Oct 21, 2026 · Market data1st of 257th29th | 9.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -6.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -23.6%price Oct 20, 2026 · Market data2nd of 230th— | -13.7%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 0.2×FY2025 · SEConly one with it35th62nd | 0.2×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | -27.3×FY2024 · SEConly one with it28th— | ———— | ———— | -27.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | —— | 1 of 14FY2025 · Scorecard5th of 5 | 8 of 16FY2025 · Scorecard2nd of 5 | 1 of 7FY2024 · Scorecard4th of 5 | 3 of 5FY2025 · Scorecard1st of 5 | 4 of 13FY2025 · Scorecard3rd of 5 | 31% passed5 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | 0 of 4FY2025 · Scorecard2nd of 2 | —— | —— | —— | 1 of 4FY2025 · Scorecard1st of 2 | 13% passed2 ranked |
| Growth checks (Higher is better) | —— | —— | —— | 0 of 2FY2025 · Scorecard3rd of 5 | 1 of 6FY2025 · Scorecard2nd of 5 | 0 of 1FY2024 · Scorecard3rd of 5 | 2 of 2FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 0% passed5 ranked |
| Profitability checks (Higher is better) | —— | —— | —— | 0 of 3FY2025 · Scorecard3rd of 5 | 3 of 5FY2025 · Scorecard1st of 5 | 0 of 2FY2024 · Scorecard3rd of 5 | 1 of 3FY2025 · Scorecard2nd of 5 | 0 of 3FY2025 · Scorecard3rd of 5 | 0% passed5 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | 1 of 2FY2025 · Scorecard3rd of 4 | 3 of 3FY2025 · Scorecard1st of 4 | 1 of 3FY2024 · Scorecard4th of 4 | —— | 3 of 4FY2025 · Scorecard2nd of 4 | 63% passed4 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | 0 of 3FY2025 · Scorecard2nd of 4 | 1 of 2FY2025 · Scorecard1st of 4 | 0 of 1FY2024 · Scorecard2nd of 4 | —— | 0 of 1FY2025 · Scorecard2nd of 4 | 0% passed4 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | 81.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 54.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 47.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 85.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 68.2%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | 1772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 1922026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 1692026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 1734 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | +0.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 3 | +3.6 pp2026-Q2 against 2026-Q1 · 13F1st of 3 | —— | —— | +0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 3 | +0.6 pp3 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | 0.0%FY2025 · SEConly one with it6th2nd | ———— | ———— | ———— | ———— | 0.0%— |
| Shareholder yield (Higher is better) | ———— | ———— | ———— | 0.0%FY2025 · SEConly one with it7th3rd | 14.8%†FY2025 · SECnot ranked: old priceold priceold price | ———— | ———— | ———— | 0.0%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Protek: Moscow Exchange, issue size times the close; Pharmacy Chain 36.6: Moscow Exchange, issue size times the close; MD Medical Group Investments: How market caps are worked out; Corvus Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; InMode Ltd.: How market caps are worked out; Adlai Nortye: How market caps are worked out; Korian: How market caps are worked out; MoonLake Immunotherapeutics: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Protek | — | — | — |
| Pharmacy Chain 36.6 | — | — | — |
| MD Medical Group Investments | — | — | — |
| Corvus Pharmaceuticals, Inc. | — | — | — |
| InMode Ltd. | 23.1%FY2025 | 91st percentile in Healthcaremedian -7.7%, 674 companies | 92nd percentile in Israelmedian -0.2%, 67 companies |
| Adlai Nortye | — | — | — |
| Korian | 5.7%FY2025 | 66th percentile in Healthcaremedian -7.7%, 674 companies | 52nd percentile in Francemedian 5.5%, 124 companies |
| MoonLake Immunotherapeutics | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Protek | Pharmacy Chain 36.6 | MD Medical Group Investments | Corvus Pharmaceuticals, Inc. | InMode Ltd. | Adlai Nortye | Korian | MoonLake Immunotherapeutics |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $371 MSEC2nd | — | $6.0 BESEF1st | — |
| 2024 | — | — | — | — | $395 MSEC2nd | — | $5.7 BESEF1st | — |
| 2023 | — | — | — | — | $492 MSEC1st | $5 MSEC2nd | — | — |
| 2022 | — | — | — | — | $454 MSEC | — | — | — |
| 2021 | — | — | — | — | $358 MSEC1st | $46 MSEC2nd | — | — |
| 2020 | — | — | — | — | $206 MSEC | — | — | — |
| 2019 | — | — | — | — | $156 MSEC | — | — | — |
| 2018 | — | — | — | — | $100 MSEC | — | — | — |
| 2017 | $4.4 BWD1st | — | — | — | $53 MSEC2nd | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Protek#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Pharmacy Chain 36.6APTK.ME · 🇷🇺 RussiaSame sector: Healthcare (Retail - Pharmacy) · Similar size: $661 M market cap against $846 M · Same country: RussiaMarket cap $661 M (Nov 19, 2026)68 of 100 (industry or sector 25 + size 28 + country 15)In the group
- MD Medical Group InvestmentsMD6B.F · 🇷🇺 RussiaSame sector: Healthcare (Medical Care Facilities) · Similar size: $216 M market cap against $846 M · Same country: RussiaMarket cap $216 M (last known, Jul 30, 2023)61 of 100 (industry or sector 25 + size 21 + country 15)In the group
- Corvus Pharmaceuticals, Inc.CRVS · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $863 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $863 M (Oct 21, 2026)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- InMode Ltd.INMD · 🇮🇱 IsraelSame sector: Healthcare (Medical Devices) · Similar size: $859 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $859 M (Aug 1, 2026) · revenue $371 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- Adlai NortyeANL · 🇰🇾 Cayman IslandsSame sector: Healthcare (Biotechnology) · Similar size: $853 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $853 M (Aug 1, 2026)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- KorianKORI.PA · 🇫🇷 FranceSame sector: Healthcare (Medical Care Facilities) · Similar size: $830 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $830 M (last known, Jul 30, 2023) · revenue $6.0 B (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- MoonLake ImmunotherapeuticsMLTX · 🇨🇭 SwitzerlandSame sector: Healthcare (Biotechnology) · Similar size: $830 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $830 M (Oct 20, 2026)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- Ardelyx, Inc.ARDX · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $822 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $822 M (Oct 9, 2026) · revenue $407 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Arjo AB (publ)ARJO-B.ST · 🇸🇪 SwedenSame sector: Healthcare (Medical Distribution) · Similar size: $819 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $819 M (Aug 1, 2026) · revenue $1.1 B (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Gyre Therapeutics, Inc.GYRE · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $818 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $818 M (Oct 29, 2026) · revenue $117 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Pacific Biosciences of California, Inc.PACB · 🇺🇸 USASame sector: Healthcare (Diagnostics and Research) · Similar size: $886 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $886 M (Oct 29, 2026) · revenue $160 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Kura Oncology, Inc.KURA · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $884 M market cap against $846 M · Ratios of the last two fiscal years on fileMarket cap $884 M (Oct 27, 2026) · revenue $67 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.